News & Perspective

Jun 20, 2012

Jun 20, 2012

ACIP reviews flu vaccine efficacy and safety, tweaks dosing for kids

(CIDRAP News) – The US Center for Disease Control and Prevention's (CDC) vaccine advisory group today heard the latest information on flu vaccine effectiveness and safety and updated its recommendation on the number of flu vaccine doses children under age 9 should receive.

May 14, 2012

May 14, 2012

Washington, other states face pertussis outbreak challenges

(CIDRAP News) – Washington state is battling its biggest pertussis outbreak in more than three decades, and cuts in local health department budgets are among the factors reported to be complicating the state's response to the epidemic.

Mar 01, 2012

Mar 01, 2012

FDA clears first quadrivalent flu vaccine

(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the first quadrivalent influenza vaccine, an inhaled live attenuated influenza vaccine developed by MedImmune and modeled after its FluMist product.

The vaccine includes a second influenza B strain, which is designed to broaden protection against circulating strains. MedImmune plans to have the quadrivalent vaccine ready for the 2013-14 flu season.

Feb 27, 2012

Feb 27, 2012

Reports detail risk of seizures in kids after flu vaccination

(CIDRAP News) – A recent set of articles in Vaccine has confirmed previous preliminary reports that young children who received influenza shots in the 2010-11 flu season had a slightly increased risk of a febrile seizure after vaccination, especially if they received a new pneumococcal vaccine at the same time.

Feb 22, 2012

Feb 22, 2012

Vaccine advisors streamline pertussis advice for adults

(CIDRAP News) – Federal vaccine advisors today simplified their pertussis immunization recommendation for adults by advising that all those over age 19—including seniors 65 and older—should receive one dose of tetanus, diphtheria, and pertussis (Tdap) vaccine if they haven't received it already.

Jan 19, 2012

Jan 19, 2012

Review renews questions about oseltamivir benefits

(CIDRAP News) – A lengthy new analysis of unpublished clinical trial data is renewing questions about the effectiveness of the influenza drug oseltamivir (Tamiflu), saying that although the drug shortens flu symptoms by about a day, there is no evidence that it reduces hospital admissions.

Nov 04, 2011

Nov 04, 2011

Flu vaccine efficacy: Time to revise public messages?

(CIDRAP News) – For many years, public health personnel have cited the estimate of 70% to 90% when talking about the level of protection afforded by seasonal influenza vaccines. But last week's meta-analysis of flu vaccine studies in The Lancet Infectious Diseases—along with several other studies in recent years—has raised the question of whether it's time to change the message about flu vaccines.

Pages

Sort Results

 

Narrow results

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»